

## The current landscape of coronavirus-host protein-protein interactions

Laure Perrin-Coccon, Olivier Diaz, Clémence Jacquemin, Valentine Barthel, Eva Ogire, Christophe Ramière, Patrice André, Vincent Lotteau, Pierre-Olivier Vidalain

#### ▶ To cite this version:

Laure Perrin-Coccon, Olivier Diaz, Clémence Jacquemin, Valentine Barthel, Eva Ogire, et al.. The current landscape of coronavirus-host protein-protein interactions. 2020. hal-02874650v1

### HAL Id: hal-02874650 https://hal.science/hal-02874650v1

Preprint submitted on 19 Jun 2020 (v1), last revised 16 Nov 2020 (v3)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

2

# The current landscape of coronavirus-host

### protein-protein interactions

4

3

- 5 Laure Perrin-Coccon<sup>1\*</sup>, Olivier Diaz<sup>1\*</sup>, Clémence Jacquemin<sup>1</sup>, Valentine Barthel<sup>1</sup>, Eva Ogire<sup>1,2</sup>,
- 6 Christophe Ramière<sup>1,3</sup>, Patrice André<sup>1</sup>, Vincent Lotteau<sup>1,\$</sup>, Pierre-Olivier Vidalain<sup>1,\$</sup>

7

- 8 <sup>1</sup> CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111,
- 9 Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France.
- 10 <sup>2</sup> UMR Processus Infectieux en Milieu Insulaire Tropical, Université de La Réunion, CNRS 9192,
- 11 INSERM U1187, IRD 249, Plateforme de Recherche CYROI, Sainte Clotilde La Réunion, France.
- 12 <sup>3</sup> Laboratoire de Virologie, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France

13

14

- \* Co-first authors equally contributed to this work
- 15 \$ Co-last authors equally contributed to this work

16

#### 17 Corresponding authors:

- 18 Vincent Lotteau : vincent.lotteau@inserm.fr
- 19 Pierre-Olivier Vidalain: pierre-olivier.vidalain@inserm.fr

20

21

22

23

24

25

26

27

28

29

#### **Abstract**

In less than twenty years, three deadly coronaviruses, SARS-CoV, MERS-CoV and SARS-CoV-2, have emerged in human population causing hundreds to hundreds of thousands of deaths. Other coronaviruses are causing epizootic representing a significant threat for both domestic and wild animals. Members of this viral family have the longest genome of all RNA viruses, and express up to 29 proteins establishing complex interactions with the host proteome. Deciphering these interactions is essential to identify cellular pathways hijacked by these viruses to replicate and escape innate immunity. Virus-host interactions also provide key information to select targets for antiviral drug development. Here, we have manually

curated the literature to assemble a unique dataset of 1311 coronavirus-host protein-protein interactions. Functional enrichment and network-based analyses showed coronavirus connections to RNA processing and translation, DNA damage and pathogen sensing, interferon production, and metabolic pathways. In particular, this global analysis pinpointed overlooked interactions with translation modulators (GIGYF2-EIF4E2), components of the nuclear pore, proteins involved in mitochondria homeostasis (PHB, PHB2, STOML2), and methylation pathways (MAT2A/B). Finally, interactome data provided a rational for the antiviral activity of some drugs inhibiting coronaviruses replication. Altogether, this work describing the current landscape of coronavirus-host interactions provides valuable hints for understanding the pathophysiology of coronavirus infections and developing effective antiviral therapies.

**Keywords:** SARS-CoV-2, coronavirus, interactome, virus-host interactions, protein-protein interactions

#### Background

Like other viruses, coronaviruses are obligate parasites and have evolved a swarm of molecular interactions for hijacking the cellular machinery to replicate. Among those, the subset of physical interactions between viral and cellular proteins — usually referred to as the virus-host interactome — is playing a key role [1]. Mapping these protein-protein interactions (PPIs) has proven extremely useful for an intimate comprehension of viral replication cycles, shedding light on the molecular modules used by viruses to replicate. Virus-host interactomics also helps to understand how viruses are detected by the immune system but also escape immune defense through the evolution of countermeasures. Finally, interactome data can be used to identify and prioritize valuable cellular targets for developing antiviral drugs as previously exemplified [2][3].

Along with genomic sequences and viral protein structures, interactome data are now considered as basic pieces of information for characterizing a virus at the molecular level. Tremendous efforts have been made to characterize the emerging SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), a positive-strand RNA virus of the *Coronaviridae* family, identified as the etiological agent of the ongoing COVID-19 respiratory disease pandemic. In a recent report, viral proteins from the SARS-CoV-2 were individually expressed in human cells

and targeted host proteins were identified by affinity purification and mass spectrometry [3]. This first virus-host interactome of the SARS-CoV-2 provided essential information on the pathways targeted by this emerging pathogen, and allowed the authors to propose a list of antiviral drug candidates to be tested. Although this represents an important step in our understanding of this virus, it is known that a single interactomic study cannot offer a comprehensive picture of a virus-host interactome [4]. Indeed, despite the use of top-notch technologies by skilled operators, each dataset contains a substantial level of unidentified interactions and artifacts that is inherent to the technology and bias the results. For instance, protein complex analysis by mass spectrometry does not distinguish direct and indirect virus-host interactions and is usually well-complemented by other technological approaches for detecting binary PPIs such as yeast two-hybrid or protein complementation assays. For these different reasons, mapping the interactome of SARS-CoV-2 can be considered as a work in progress.

As a contribution to this effort, we used an orthogonal approach by looking at virushost interactions already reported for other coronaviruses. This compendium of data gathered from literature was used to identify both overlapping and complementary interactions to build the framework of a generic coronavirus-host interactome. Although each coronavirus is expected to have evolved specific interactions accounting for host range specificity and pathogenesis, a majority of coronavirus-host PPIs are most likely shared across multiple species considering the high level of conservation of the coronavirus replication machinery [5]. Gathering interactomic data from several related viruses is an efficient way to fill in the blanks from literature and identify cellular pathways and complexes that are common coronaviruses targets. Although a proof of concept of this approach was recently established [5], we were able to retrieve 10 times more interactions from literature to assemble an unmatched collection of coronavirus-host interactions. In addition, we identified PPIs that could explain the antiviral activity of approved drugs previously characterized as coronaviruses inhibitors, thus strengthening their interest against SARS-CoV-2.

#### **Results and discussion**

#### Gathering coronavirus-host interactions from literature

Several members of the *Coronaviridae* family are pathogenic in human and animals, and represent a threat for public health and livestock. To date, seven coronaviruses have been

reported to infect human (Human coronaviruses; HCoVs). HCoV-NL63 and HCoV-229E (from the  $\alpha$  genus) and HCoV-HKU1 and HCoV-OC43 (from the  $\beta$  genus) are responsible for common cold. In addition, three  $\beta$  coronaviruses, MERS-CoV (Middle East respiratory syndrome-related coronavirus), SARS-CoV and SARS-CoV-2, are associated to life-threatening respiratory diseases in human. Important animal coronaviruses include but are not limited to TGEV (Transmissible Gastroenteritis Virus,  $\alpha$  genus), PRCV (Porcine Respiratory Coronavirus,  $\alpha$ genus), PEDV (Porcine Epidemic Diarrhea Virus,  $\alpha$  genus), MHV (Murine Hepatitis Virus,  $\beta$ genus), IBV (Infectious Bronchitis Virus,  $\gamma$  genus), and PDCoV (Porcine Deltacoronavirus,  $\delta$ genus). The genome of coronaviruses is a positive-strand RNA with two third at the 5' end occupied by the overlapping open reading frames ORF1a and b that encode non-structural proteins (nsPs). The genes encoding structural proteins and a variable number of accessory factors are nested at the 3' end of the genome. Viral genomes are directly translated by host cell's ribosomes into a large polyprotein encoded by the ORF1a/b gene. This polyprotein is cleaved into 16 non-structural proteins (nsP1-16), except for PDCoV where nsP1 is missing. Most of these nsPs assemble into a complex that replicates viral genome and synthesizes subgenomic mRNA from the other genes to express structural proteins S, E, M and N and the additional accessory factors.

To collect virus-host interaction data for the 13 coronaviruses mentioned above (*i.e.* HCoV-NL63, HCoV-229E, HCoV-HKU1, HCoV-OC43, MERS-CoV, SARS-CoV, SARS-CoV-2, TGEV, PRCV, PEDV, MHV, IBV, and PDCoV), we interrogated the PubMed database using the following query sentence: "virus name"[Title/Abstract] AND (bind\*[Title/Abstract] OR interact\*[Title/Abstract]). After careful analysis of the retrieved abstracts, 112 publications explicitly reporting physical interactions between viral and host proteins were selected (Figure 1a). These publications were analyzed by at least two curators to determine which methods were used to characterize the reported interactions, and collected information was gathered in a single data file (Supplementary Table 1). In total, this file contains 1,544 entries. As 133 interactions were characterized by more than one method or were detected across multiple host species, and that 23 interactions were reported in two or more independent publications, this corresponds to 1,311 distinct virus-host interactions involving 1,139 different host proteins (orthologous proteins from different host species were collapsed; Figure 1a and Supplementary Table 2). A majority of the reported interactions (92%) were from four viruses

- 1 for which high-throughput interactomic methods have been applied: MHV, SARS-CoV-2, SARS-
- 2 CoV, and IBV (Figure 1b, Supplementary Table 3)[6][7][3][8][9][10][11][12].

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

#### Shared interactions and host protein targets across multiple coronaviruses

We then looked for interactions that are conserved across two or more viruses. To perform this analysis, orthologous proteins from different host species were collapsed as above. In total, we identified 51 orthologous interactions in the dataset, providing a robust network of shared PPIs between several coronaviruses (Figure 1c; Supplementary Table 4). Membrane receptors shared by several coronaviruses (ACE2, ANPEP) as well as cellular proteases involved in the processing of the spike glycoproteins S (TMPRSS2, TMPRSS11D, CTSB, CTSL, FURIN) were highlighted. Multiple interactions between the nucleoprotein N and host factors involved in mRNA synthesis, maturation, nuclear export, translation and stability were also identified (EEF1A1, PABPC1, PABPC4, RNRNPA1, HNRNPU, YBX1, LARP1), including ribosomal components (RPS9, RPS13, RPS19, RPL26), multiple helicases (UPF1, MOV10, DHX9, DDX21, DDX1) and key components of the innate antiviral response (G3BP1, G3BP2, PRKRA). GSK3A/B were previously reported to phosphorylate the viral nucleocapsid of MHV to recruit DDX1 [13]. In the assembled interactome dataset, GSK3A/B were also found to interact with N of IBV and SARS-CoV, and interaction of DDX1 with both N and nsP14 of IBV and TGEV as well as nsP14 of SARS-CoV were also reported [12][14][15][16]. This analysis also highlights the well-known function of nsP3 in coronavirus escape from the innate immune response through interactions with both ubiquitination/ISGylation factors (RCHY1, ISG15) and key antiviral factors (STING1, TBK1, IRF3)[11][17][18][19][20][21]. Other remarkable interactions are between nsP2, EIF4E2 (4EHP) and GIGYF2, which are two components of a complex repressing mRNA translation [22]. Although EIF4E2 and GIGYF2 were identified by highthroughput interactomic applied to SARS-CoV, SARS-CoV-2 and MHV [3][9][6], they were never investigated in details. These highly conserved interactions suggest a crucial role of nsP2 in regulating viral and/or cellular mRNA translation and degradation.

We also looked for host proteins interacting with several coronaviruses, but not necessarily targeted by the same viral proteins. Because coronavirus proteins assemble into large molecular complexes, the same host protein can be captured, either directly or indirectly, by distinct viral proteins used as bait. In total, 106 of the 1,139 host proteins from the dataset (9.3%) were shared by at least two coronaviruses, including 50 host proteins

involved in the conserved interactions displayed in Figure 1c. Shared targets of different viruses are illustrated in Figure 1d and details are provided in Supplementary Table 5. Interestingly, several host factors involved in viral RNA sensing (DDX58, IFIH1, PRKRA), DNA sensing (STING1) or downstream signalling to activate the innate immune response (TRAF3, TBK1, IKBKE, IKBKB, ISG15, IRF3) were targeted by unrelated viral proteins (Figure 1e)[3][20][21][23][24][25][26][27][28][29][30][31][32][33][34][35][36]. This highlights the importance of these interactions for coronaviruses, but is puzzling from an evolutionary perspective. Indeed, this suggests that coronaviruses have evolved different but convergent strategies to target these innate immunity factors. An alternative explanation is that multiple proteins of a virus target the same host factor in redundant ways, although this information is not present in the current interaction datasets yet. The two hypotheses are not mutually exclusive and this will require further investigation to be addressed.

#### Enrichment analysis for specific cellular pathways.

To identify cellular complexes or pathways that are enriched in the list of host factors interacting with coronavirus proteins, we retrieved associated KEGG annotations and calculated statistical enrichments using the DAVID functional annotation tool [37][38]. To evaluate the interest of combining interactome data from several coronaviruses, we analyzed host targets of SARS-CoV-2 alone (Table 1a), of human highly-pathogenic coronaviruses (Table 1b) and of all coronaviruses (Table 1c). Although SARS-CoV-2 restricted analysis only identified "Protein processing in endoplasmic reticulum" and "RNA transport" as significantly enriched KEGG pathways, expending the dataset doubled the number of host factors falling in these two categories and unraveled enrichments for "Ribosome", "RIG-I-like receptor signaling", "Endocytosis", "Spliceosome" and "Phagosome" pathways (Table 1c and Supplementary Table 6). Up to 69% of the KEGG-annotated eukaryotic ribosomal proteins and 18% of the spliceosome components are targeted by coronavirus proteins, thus demonstrating the importance for these viruses to control the mRNA processing and translation machinery. We used KEGG Mapper to highlight targeted host proteins on schematic representation of the most enriched cellular pathways (Figure 2a-d)[39]. As shown in Figure 2a, several factors involved in protein export were targeted together with components of the unfolded protein response/endoplasmic-reticulum-associated protein degradation (ERAD) pathway. This observation is in line with numerous reports showing that coronavirus replication induces a

strong ER stress response, and that virulence factors expressed by these viruses aim at controlling and even subvert this cellular response to assemble convoluted and doublemembrane vesicles [40]. Several regulators of intracellular trafficking and vesicular transport associated to endocytic compartments, especially late endosomes and multivesicular bodies, are also hijacked (Figure 2b). These interactions most likely contribute to the entry, assembly and/or secretion of viral particles [41]. The nuclear pore complex (NPC) and translation initiation factors are also overrepresented in the list of host proteins targeted by coronaviruses, which accounts for the statistical enrichment of KEGG annotation "RNA transport" (Figure 2c). The number of Interactions with translation initiation factors, together with ribosomal components, reflects the intense hijacking of translational machinery by coronaviruses [6]. Some of these interactions could also prevent the translational shut-off associated to antiviral and unfolded protein responses as demonstrated for the ORF7 of TGEV [42], while others could help the virus to control host protein expression [43]. On the contrary, viral factors interacting with components of the NPC to interfere with the nuclear export of cellular mRNA and with the antiviral response are poorly documented [44][45]. Finally, this analysis highlighted multiple interactions with components of the RIG-like receptor pathways (Figure 2d), that is essential for viral RNA detection and the induction of interferon secretion. This includes the multi-targeted host factors already presented in Figure 1e but also additional proteins such as the adaptors MAVS (IPS1), TBKBP1 (SINTBAD), TRAF2 and TRAF6, the negative (NLRX1) or positive (DDX3X) regulators, and kinases such as RIPK1 (RIP1) or IKBKG (ΙΚΚγ)[3][12][46][47]. Altogether, this provides an overview of cellular pathways that are major targets of coronaviruses.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

Despite several reports showing that viruses have evolved strategies to finely tune cellular metabolism for promoting their replication [48], no statistical enrichment for components of a specific metabolic pathway was identified. We thus conducted an orientated analysis by looking at potential overlaps between the list of host proteins targeted by coronaviruses and the 1226 proteins annotated in the "Metabolism pathways" of the KEGG database. In total, 62 proteins were identified at the intersection of the two lists, and were clustered according to their specific metabolic pathways using KEGG annotation (Figure 3). Multiple interactions were identified with factors involved in nucleotide metabolism, including enzymes of the nucleo-tide/-side biosynthesis and degradation pathways (IMPDH2, RRM2, ADK, DCTPP1, NT5C2, XDH, ADA) and more surprisingly, several components of cellular

DNA and RNA polymerases (POLA1, POLA2, POLD1, PRIM1, PRIM2 and POLR2B). These interactions could contribute to the DNA replication stress and cell cycle arrest induced by coronaviruses as previously suggested for the nsP13-POLD1 interaction, but their role is still poorly defined [49]. Several components of complex I of the mitochondrial respiratory chain were also targeted (NDUF9/10/13), as well as V-type ATPase subunits involved in the acidification of cellular compartments, especially during phagocytosis (Supplementary Table 6). Lipid and glycan biosynthesis enzymes were highly represented, in line with previous reports showing the dependence of coronaviruses to these two pathways [50][51]. In the "amino acid metabolism" cluster, both methionine adenosyltransferase 2A (MAT) and the regulatory subunit MAT2B were present (captured by ORF3 from PEDV and nsP9 of SARS-CoV-2, respectively). MAT2A catalyzes the synthesis of S-adenosyl-L-methionine, the major biological methyl donor. This may indicate that coronaviruses critically need S-adenosyl methionine (SAM) to methylate the viral RNA cap structures to allow transcription and prevent their recognition by cellular innate immunity receptors [52]. In the same cluster were also found two methyltransferases (COMT, DNMT1). Although the significance of targeting COMT (Catechol O-Methyl Transferase), an enzyme involved in catecholamine synthesis, remains elusive, interactions with DNMT1 could be a mechanism used by coronaviruses to alter the epigenetic landscape of infected cells as observed for other viruses [53]. Finally, coronavirus proteins also interacted with several host factors flagged as "central carbon metabolism" enzymes. This cluster includes multiple enzymes contributing to protein sialylation (GNE, NANS) and glycosylation (UGP2), inositol synthesis (MTMR3, ISYNA1), and two enolases (ENO1, ENO3) whose interactions with viral proteins could modulate glycolysis and energy supply for promoting viral growth. Altogether, this analysis suggests that, although the completeness of the available dataset does not allow statistical validation, coronaviruses extensively interact with metabolic enzymes.

25 26

27

28

29

30

31

32

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

#### A network-based identification of host protein complexes targeted by coronaviruses

To identify densely connected regions in the list of targeted host proteins, we used the web-based application Metascape [54]. PPIs from the human interactome were retrieved from the BioGrid knowledgebase, InWeb\_IM and Omni-Path, and densely connected regions were extracted using the MCODE algorithm. As no result could be retrieved when the full list of 1139 host proteins was submitted to Metascape, we limited this analysis to the core list of

179 host proteins for which multiple experimental evidences exist to support an interaction with coronavirus proteins. We also excluded the interactors of the spike glycoproteins that are already well-characterized and skewed the analysis of the other virus-host PPIs (Supplementary Table 7). From the list of 157 host proteins, this identified 7 protein clusters whose biological role was determined by Metascape using GO enrichment analysis (Figure 4)[55][56] and largely confirmed our analyses discussed above. The functional annotations enriched in the four largest clusters were "mRNA catabolic process", "Regulation of type I interferon production", "Response to virus", and "Translation". Interestingly, this analysis highlighted the link between XRCC5/6 dimers and components of the RIG-like receptor pathway. XRCC5/6 binds to DNA double-strand break ends and activates the catalytic activity of DNA-PK to promote DNA repair. In the cytosolic compartment, it also participates to type I interferon induction in response to foreign DNA [57]. Furthermore, it has been shown that DNA-PK is activated and participates to interferon induction in dengue virus-infected cells [58], and that NS5A from Hepatitis C virus (HCV) is phosphorylated by this kinase [59]. The targeting of XRCC5 and 6 by the N protein of IBV and OC43 [12][60] suggests that these proteins also play a role in the induction of innate immunity and/or the replication of coronaviruses. Three clusters of only three components were also identified. The first one includes PHB, PHB2 and STOML2 that are all members of the stomatin-prohibitin-flotillin-HfIC/K (SPFH) superfamily. These proteins colocalize at the inner mitochondrial membrane where they assemble into ring-like structures [61]. They regulate mitochondrial homeostasis, and are involved in processes such as mitophagy and mitochondrial fusion. By targeting these proteins, coronavirus proteins may also impact key mitochondrial functions such as respiration, lipid biosynthesis and innate immunity. The second small cluster is composed of MARK1, 2, and 3, three Ser/Thr protein kinases involved in the control of cell polarity, microtubule stability and cancer. MARK proteins have been reported to interact with nsP2 of MHV, nsP13 of SARS-CoV, and ORF9B of both SARS-CoV and SARS-CoV-2 [3][6][7][8]. Although their role in coronavirus replication is unknown, they could contribute to viral trafficking as they control microtubule dynamics and vesicular transport. Interestingly, several approved drugs inhibiting MARK kinases were recently proposed as potential antivirals against coronaviruses and especially SARS-CoV-2 [3]. The last cluster is composed of the cytoskeleton and microtubule-associated proteins DCTN2, FBF1 and CKAP5 that could participate to the transport of viral complexes within infected cells.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

#### Overlaps with functional in vitro screenings of chemical drug libraries

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

To provide a rational for the antiviral activity of some drugs targeting cellular factors, we determined to what extent the coronavirus-host interactome intersects the large-scale chemical screenings of antivirals against coronaviruses. We selected four publications reporting in vitro screening of chemical libraries against SARS-CoV, MERS-CoV and HCoV-OC43 [62][63][64][65]. In total, 77 molecules were identified for their antiviral activity against at least one coronavirus. Chloroquine was identified in all four publications, amodiaquine and loperamide were identified in three of them, and chlorpromazine, cycloheximide, emetine, and hydroxychloroquine were cited in two publications. Then we searched for cellular targets of these 77 molecules using the Drug Repurposing Hub database [66], and looked for overlaps with the list of 1139 host proteins interacting with coronaviruses. We identified 10 drugs and 14 host proteins matching these criteria (Figure 5). Anisomycine, cycloheximide, emetine and homoarringtonine are translational inhibitors interacting with ribosomal components. As coronaviruses exhibit tight interactions with translation initiation factors and recruit multiple ribosomal components (Table 1c and Figure 4), this could explain the antiviral effect of these three drugs. Three molecules, fluphenazine, loperamide and chlorpromazine, target calmodulin (CALM1) which interacts with ORF3 from PEDV [34]. CALM1 is a Ca<sup>2+</sup>-binding messenger protein that regulates the function of numerous proteins. In particular, it controls the activity of the multifunctional CAMKII proteins (Ca2+/calmodulin-dependent protein kinase II), which are targeted by coronaviruses as well. Indeed, CAMK2D and CAMK2G interact with nsP3 of SARS-CoV and nsP2 of MHV, respectively (Supplementary Table 1)[6][11]. Furthermore, ACE2 receptor of SARS-CoV-2, SARS-CoV, HCoV-NL63 and HCoV-229E, and CEACAM1 receptor of MHV are also calmodulin-binding proteins [67][68][69]. Although fluphenazine, loperamide and chlorpromazine have multiple targets in host cells, interactions with CALM1 could account for the inhibition of coronaviruses by these drugs. Clomipramine, which is structurally and functionally closely related to chlorpromazine, was also selected in the analysis as a consequence of its interaction with GSTP1, one of the glutathione Stransferase isoenzymes. This analysis also highlighted interactions between coronavirus proteins and host factors involved in nucleotide biosynthesis. First, nsP14 interacts with inosine-5'-monophosphate dehydrogenase 2 (IMPDH2), a key enzyme of de novo purine biosynthesis pathway. The inhibitor mycophenolic acid, that is depleting cells in purine, is wellknown for its broad-spectrum antiviral activity and is in a list of drug candidates proposed against SARS-CoV-2 [3]. In addition, the analysis pinpointed to the interaction of nsP2 from MHV with the host enzyme RRM2, one of the two subunits of ribonucleotide reductase that is inhibited by gemcitabine. This interaction between an enzyme involved in deoxyribonucleotide synthesis and an RNA virus protein was unexpected. However, RRM2 was previously reported to interact with NS5B from HCV, preventing its degradation and promoting the replication of this RNA virus [70]. Furthermore, gemcitabine has been shown to inhibit the replication of many different RNA viruses by blocking cellular DNA replication. Indeed, this induces a genomic stress that triggers the innate antiviral response [71]. Thus, RNA viruses could have evolved interactions with cellular enzymes involved in nucleoside/nucleotide synthesis such as IMPDH and RRM2 to sustain DNA replication and prevent genotoxic stress.

#### **Concluding remarks**

We have assembled a large coronavirus-host interactome built upon 1311 PPIs retrieved from literature. Functional annotation and network-based analyses highlighted targeted cellular pathways and modules. Overall, mRNA processing and transport, translation initiation and protein translation, endosomal trafficking, and innate immunity were the most enriched pathways. This conclusion is consistent with previous reports identifying these biological processes as targets of specific coronaviruses. The global analysis suggest that these interactions are highly conserved across most if not all coronaviruses. We also pinpointed to a couple of small protein complexes that appear particularly relevant to coronavirus infection but were not previously investigated. This includes in particular the EIF4E2-GIGYF2 dimer involved in the repression of protein translation, the MAT2A-MAT2B complex controlling SAM synthesis, the DNA-PK kinase that contributes to interferon induction, and the mitochondrial proteins PHB, PHB2 and STOML2 regulating mitophagy. Multiple evidences also support a key role of the MARK kinases. Finally, we identified a dozen of host factors that are bound by coronavirus proteins and functionally modulated by compounds selected from antiviral screens, giving hints to explain the inhibition of coronavirus replication by these drugs. Among these molecules is chlorpromazine, an antipsychotic drug that is currently evaluated in a clinical trial against SARS-CoV-2. In conclusion, this work has highlighted the importance of several neglected coronavirus-host interactions that deserve to be further investigated. It also

- 1 illustrates the interest of combining virus-host interactome datasets from different
- 2 laboratories, obtained by different approaches and generated in various cell types to increase
- 3 coverage and get closer to completeness.

- 5 **Abbreviations:** SARS-CoV: Severe acute respiratory syndrome coronavirus, MERS-CoV: Middle
- 6 East respiratory syndrome-related coronavirus, PPIs: Protein-Protein Interactions, HCoV:
- 7 Human coronavirus, TGEV: Transmissible Gastroenteritis Virus, PRCV: Porcine Respiratory
- 8 Coronavirus, PEDV: Porcine Epidemic Diarrhea Virus, MHV: Murine Hepatitis Virus, IBV:
- 9 Infectious Bronchitis Virus, PDCoV: Porcine Deltacoronavirus, nsPs: non-structural proteins,
- 10 ERAD: endoplasmic-reticulum-associated protein degradation, ER: endoplasmic reticulum.

11

#### 12 **Declarations**

- 13 Ethics approval and consent to participate
- 14 Not applicable
- 15 **Consent for publication**
- 16 Not applicable

#### 17 Availability of data and materials

- 18 All data generated or analyzed during this study are included in this published article and its
- 19 supplementary information file.

#### 20 **Competing interests**

21 The authors declare that they have no competing interests.

#### 22 Funding

- 23 This work was supported by the Institut National de la Santé et de la Recherche Médicale
- 24 (INSERM) and the Centre National de Recherche Scientifique (CNRS) and Université de Lyon.
- 25 EO is supported by the Conseil Régional de l'île de La Réunion DIRED 20181189.

#### 26 Authors'contributions

- 1 LPC, OD, CJ, VB, EO collected data from literature. LPC, OD and POV analyzed the data and
- 2 generated the figures. POV and VL wrote the manuscript. PA and CR provided advises to
- 3 analyze data and build the figures, and corrected the manuscript. All authors read and
- 4 approved the final manuscript.
- 5 Acknowledgements
- 6 Not applicable

#### 1 References

- 2 1. Fung TS, Liu DX. Human Coronavirus: Host-Pathogen Interaction. Annu Rev Microbiol.
- 3 2019;73:529–57.
- 4 2. de Chassey B, Meyniel-Schicklin L, Vonderscher J, André P, Lotteau V. Virus-host
- 5 interactomics: new insights and opportunities for antiviral drug discovery. Genome Med.
- 6 2014;6:115.
- 7 3. Gordon DE, Jang GM, Bouhaddou M, Xu J, Obernier K, White KM, et al. A SARS-CoV-2
- 8 protein interaction map reveals targets for drug repurposing. Nature. 2020;
- 9 4. Lum KK, Cristea IM. Proteomic approaches to uncovering virus-host protein interactions
- during the progression of viral infection. Expert Rev Proteomics. 2016;13:325–40.
- 5. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for
- novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6:14.
- 13 6. V'kovski P, Gerber M, Kelly J, Pfaender S, Ebert N, Braga Lagache S, et al. Determination
- 14 of host proteins composing the microenvironment of coronavirus replicase complexes by
- proximity-labeling. Elife. 2019;8.
- 7. Vidalain P-O, Jacob Y, Hagemeijer MC, Jones LM, Neveu G, Roussarie J-P, et al. A field-
- proven yeast two-hybrid protocol used to identify coronavirus-host protein-protein interactions.
- 18 Methods Mol Biol. 2015;1282:213–29.
- 8. Pfefferle S, Schöpf J, Kögl M, Friedel CC, Müller MA, Carbajo-Lozoya J, et al. The SARS-
- 20 coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus
- 21 inhibitors. PLoS Pathog. 2011;7:e1002331.
- 9. Cornillez-Ty CT, Liao L, Yates JR, Kuhn P, Buchmeier MJ. Severe acute respiratory
- 23 syndrome coronavirus nonstructural protein 2 interacts with a host protein complex involved in
- 24 mitochondrial biogenesis and intracellular signaling. J Virol. 2009;83:10314–8.
- 25 10. Chen J-Y, Chen W-N, Poon K-MV, Zheng B-J, Lin X, Wang Y-X, et al. Interaction between
- 26 SARS-CoV helicase and a multifunctional cellular protein (Ddx5) revealed by yeast and
- 27 mammalian cell two-hybrid systems. Arch Virol. 2009;154:507–12.
- 28 11. Ma-Lauer Y, Carbajo-Lozoya J, Hein MY, Müller MA, Deng W, Lei J, et al. p53 down-
- 29 regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro
- via E3 ubiquitin ligase RCHY1. Proc Natl Acad Sci USA. 2016;113:E5192-5201.
- 31 12. Emmott E, Munday D, Bickerton E, Britton P, Rodgers MA, Whitehouse A, et al. The
- 32 cellular interactome of the coronavirus infectious bronchitis virus nucleocapsid protein and
- functional implications for virus biology. J Virol. 2013;87:9486–500.
- 34 13. Wu C-H, Chen P-J, Yeh S-H. Nucleocapsid phosphorylation and RNA helicase DDX1
- 35 recruitment enables coronavirus transition from discontinuous to continuous transcription. Cell
- 36 Host Microbe. 2014;16:462–72.
- 37 14. Wu C-H, Yeh S-H, Tsay Y-G, Shieh Y-H, Kao C-L, Chen Y-S, et al. Glycogen synthase
- 38 kinase-3 regulates the phosphorylation of severe acute respiratory syndrome coronavirus
- nucleocapsid protein and viral replication. J Biol Chem. 2009;284:5229–39.
- 40 15. Xu L, Khadijah S, Fang S, Wang L, Tay FPL, Liu DX. The cellular RNA helicase DDX1
- 41 interacts with coronavirus nonstructural protein 14 and enhances viral replication. J Virol.
- 42 2010;84:8571–83.
- 43 16. Zhou Y, Wu W, Xie L, Wang D, Ke Q, Hou Z, et al. Cellular RNA Helicase DDX1 Is
- 44 Involved in Transmissible Gastroenteritis Virus nsp14-Induced Interferon-Beta Production.
- 45 Front Immunol. 2017;8:940.
- 46 17. Daczkowski CM, Dzimianski JV, Clasman JR, Goodwin O, Mesecar AD, Pegan SD.
- 47 Structural Insights into the Interaction of Coronavirus Papain-Like Proteases and Interferon-
- 48 Stimulated Gene Product 15 from Different Species. J Mol Biol. 2017;429:1661–83.
- 49 18. Ratia K, Kilianski A, Baez-Santos YM, Baker SC, Mesecar A. Structural Basis for the
- 50 Ubiquitin-Linkage Specificity and delSGylating activity of SARS-CoV papain-like protease.

- 1 PLoS Pathog. 2014;10:e1004113.
- 2 19. Sun L, Xing Y, Chen X, Zheng Y, Yang Y, Nichols DB, et al. Coronavirus papain-like
- 3 proteases negatively regulate antiviral innate immune response through disruption of STING-
- 4 mediated signaling. PLoS ONE. 2012;7:e30802.
- 5 20. Devaraj SG, Wang N, Chen Z, Chen Z, Tseng M, Barretto N, et al. Regulation of IRF-3-
- 6 dependent innate immunity by the papain-like protease domain of the severe acute respiratory
- 7 syndrome coronavirus. J Biol Chem. 2007;282:32208–21.
- 8 21. Zheng D, Chen G, Guo B, Cheng G, Tang H. PLP2, a potent deubiquitinase from murine
- 9 hepatitis virus, strongly inhibits cellular type I interferon production. Cell Res. 2008;18:1105–
- 10 13
- 22. Morita M, Ler LW, Fabian MR, Siddiqui N, Mullin M, Henderson VC, et al. A novel 4EHP-
- 12 GIGYF2 translational repressor complex is essential for mammalian development. Mol Cell
- 13 Biol. 2012;32:3585–93.
- 23. Siu K-L, Kok K-H, Ng M-HJ, Poon VKM, Yuen K-Y, Zheng B-J, et al. Severe acute
- respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding
- the formation of TRAF3.TANK.TBK1/IKKepsilon complex. J Biol Chem. 2009;284:16202–
- 17 9.
- 18 24. Fang P, Fang L, Ren J, Hong Y, Liu X, Zhao Y, et al. Porcine Deltacoronavirus Accessory
- 19 Protein NS6 Antagonizes Interferon Beta Production by Interfering with the Binding of RIG-
- 20 I/MDA5 to Double-Stranded RNA. J Virol. 2018;92.
- 25. Chen X, Yang X, Zheng Y, Yang Y, Xing Y, Chen Z. SARS coronavirus papain-like
- 22 protease inhibits the type I interferon signaling pathway through interaction with the STING-
- 23 TRAF3-TBK1 complex. Protein Cell. 2014;5:369–81.
- 26. Siu K-L, Chan C-P, Kok K-H, Chiu-Yat Woo P, Jin D-Y. Suppression of innate antiviral
- 25 response by severe acute respiratory syndrome coronavirus M protein is mediated through the
- 26 first transmembrane domain. Cell Mol Immunol. 2014;11:141–9.
- 27. Chen J, Fang P, Wang M, Peng Q, Ren J, Wang D, et al. Porcine deltacoronavirus
- 28 nucleocapsid protein antagonizes IFN-β production by impairing dsRNA and PACT binding to
- 29 RIG-I. Virus Genes. 2019;55:520–31.
- 30 28. Likai J, Shasha L, Wenxian Z, Jingjiao M, Jianhe S, Hengan W, et al. Porcine
- 31 Deltacoronavirus Nucleocapsid Protein Suppressed IFN-β Production by Interfering Porcine
- 32 RIG-I dsRNA-Binding and K63-Linked Polyubiquitination. Front Immunol. 2019;10:1024.
- 33 29. Yang Y, Ye F, Zhu N, Wang W, Deng Y, Zhao Z, et al. Middle East respiratory syndrome
- 34 coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and
- 35 nuclear targets. Sci Rep. 2015;5:17554.
- 36 30. Siu K-L, Yeung ML, Kok K-H, Yuen K-S, Kew C, Lui P-Y, et al. Middle east respiratory
- 37 syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses
- 38 PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. J Virol.
- 39 2014;88:4866–76.
- 40 31. Ding Z, Fang L, Yuan S, Zhao L, Wang X, Long S, et al. The nucleocapsid proteins of
- 41 mouse hepatitis virus and severe acute respiratory syndrome coronavirus share the same IFN-
- 42 β antagonizing mechanism: attenuation of PACT-mediated RIG-I/ MDA5 activation.
- 43 Oncotarget. 2017;8:49655–70.
- 32. Wang G, Chen G, Zheng D, Cheng G, Tang H. PLP2 of mouse hepatitis virus A59 (MHV-
- 45 A59) targets TBK1 to negatively regulate cellular type I interferon signaling pathway. PLoS
- 46 ONE. 2011;6:e17192.
- 47 33. Ding Z, Fang L, Jing H, Zeng S, Wang D, Liu L, et al. Porcine epidemic diarrhea virus
- 48 nucleocapsid protein antagonizes beta interferon production by sequestering the interaction
- 49 between IRF3 and TBK1. J Virol. 2014;88:8936–45.
- 50 34. Kaewborisuth C, Yingchutrakul Y, Roytrakul S, Jongkaewwattana A. Porcine Epidemic

- 1 Diarrhea Virus (PEDV) ORF3 Interactome Reveals Inhibition of Virus Replication by Cellular
- 2 VPS36 Protein. Viruses. 2019;11.
- 3 35. Fang X, Gao J, Zheng H, Li B, Kong L, Zhang Y, et al. The membrane protein of SARS-
- 4 CoV suppresses NF-kappaB activation. J Med Virol. 2007;79:1431–9.
- 5 36. Wong HH, Fung TS, Fang S, Huang M, Le MT, Liu DX. Accessory proteins 8b and 8ab of
- 6 severe acute respiratory syndrome coronavirus suppress the interferon signaling pathway by
- 7 mediating ubiquitin-dependent rapid degradation of interferon regulatory factor 3. Virology.
- 8 2018;515:165–75.
- 9 37. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids
- 10 Res. 2000;28:27–30.
- 38. Dennis G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database
- for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4:P3.
- 13 39. Kanehisa M, Sato Y. KEGG Mapper for inferring cellular functions from protein sequences.
- 14 Protein Sci. 2020;29:28–35.
- 40. Fung TS, Huang M, Liu DX. Coronavirus-induced ER stress response and its involvement
- in regulation of coronavirus-host interactions. Virus Res. 2014;194:110–23.
- 17 41. Hagemeijer MC, Rottier PJM, de Haan CAM. Biogenesis and dynamics of the coronavirus
- replicative structures. Viruses. 2012;4:3245–69.
- 19 42. Cruz JLG, Sola I, Becares M, Alberca B, Plana J, Enjuanes L, et al. Coronavirus gene 7
- 20 counteracts host defenses and modulates virus virulence. PLoS Pathog. 2011;7:e1002090.
- 21 43. Xiao H, Xu LH, Yamada Y, Liu DX. Coronavirus spike protein inhibits host cell translation
- by interaction with eIF3f. PLoS ONE. 2008;3:e1494.
- 23 44. Gomez GN, Abrar F, Dodhia MP, Gonzalez FG, Nag A. SARS coronavirus protein nsp1
- 24 disrupts localization of Nup93 from the nuclear pore complex. Biochem Cell Biol.
- 25 2019;97:758–66.
- 26 45. Huang S-H, Lee T-Y, Lin Y-J, Wan L, Lai C-H, Lin C-W. Phage display technique
- 27 identifies the interaction of severe acute respiratory syndrome coronavirus open reading frame
- 28 6 protein with nuclear pore complex interacting protein NPIPB3 in modulating Type I
- interferon antagonism. J Microbiol Immunol Infect. 2017;50:277–85.
- 30 46. Shi C-S, Qi H-Y, Boularan C, Huang N-N, Abu-Asab M, Shelhamer JH, et al. SARS-
- 31 coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and
- the MAVS/TRAF3/TRAF6 signalosome. J Immunol. 2014;193:3080–9.
- 47. Wang D, Fang L, Shi Y, Zhang H, Gao L, Peng G, et al. Porcine Epidemic Diarrhea Virus
- 34 3C-Like Protease Regulates Its Interferon Antagonism by Cleaving NEMO. J Virol.
- 35 2016;90:2090–101.
- 36 48. Sanchez EL, Lagunoff M. Viral activation of cellular metabolism. Virology. 2015;479–
- 37 480:609–18.
- 38 49. Xu LH, Huang M, Fang SG, Liu DX. Coronavirus infection induces DNA replication stress
- 39 partly through interaction of its nonstructural protein 13 with the p125 subunit of DNA
- 40 polymerase δ. J Biol Chem. 2011;286:39546–59.
- 41 50. Yan B, Chu H, Yang D, Sze K-H, Lai P-M, Yuan S, et al. Characterization of the Lipidomic
- 42 Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling
- 43 upon Coronavirus Replication. Viruses. 2019;11.
- 51. Yuan S, Chu H, Chan JF-W, Ye Z-W, Wen L, Yan B, et al. SREBP-dependent lipidomic
- reprogramming as a broad-spectrum antiviral target. Nat Commun. 2019;10:120.
- 46 52. Aouadi W, Blanjoie A, Vasseur J-J, Debart F, Canard B, Decroly E. Binding of the Methyl
- 47 Donor S-Adenosyl-l-Methionine to Middle East Respiratory Syndrome Coronavirus 2'-O-
- 48 Methyltransferase nsp16 Promotes Recruitment of the Allosteric Activator nsp10. J Virol.
- 49 2017;91.
- 50 53. Schäfer A, Baric RS. Epigenetic Landscape during Coronavirus Infection. Pathogens.

- 1 2017;6.
- 2 54. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape
- 3 provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun.
- 4 2019;10:1523.
- 5 55. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology:
- 6 tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25–9.
- 7 56. The Gene Ontology Consortium. The Gene Ontology Resource: 20 years and still GOing
- 8 strong. Nucleic Acids Res. 2019;47:D330–8.
- 9 57. Morchikh M, Cribier A, Raffel R, Amraoui S, Cau J, Severac D, et al. HEXIM1 and NEAT1
- 10 Long Non-coding RNA Form a Multi-subunit Complex that Regulates DNA-Mediated Innate
- 11 Immune Response. Mol Cell. 2017;67:387-399.e5.
- 58. Vetter ML, Rodgers MA, Patricelli MP, Yang PL. Chemoproteomic profiling identifies
- changes in DNA-PK as markers of early dengue virus infection. ACS Chem Biol. 2012;7:2019–
- **14** 26.
- 59. Pan T-C, Lo C-W, Chong WM, Tsai C-N, Lee K-Y, Chen P-Y, et al. Differential Proteomics
- 16 Reveals Discrete Functions of Proteins Interacting with Hypo- versus Hyper-phosphorylated
- NS5A of the Hepatitis C Virus. J Proteome Res. 2019;18:2813–25.
- 18 60. Lai FW, Stephenson KB, Mahony J, Lichty BD. Human coronavirus OC43 nucleocapsid
- 19 protein binds microRNA 9 and potentiates NF-κB activation. J Virol. 2014;88:54–65.
- 20 61. Hernando-Rodríguez B, Artal-Sanz M. Mitochondrial Quality Control Mechanisms and the
- 21 PHB (Prohibitin) Complex. Cells. 2018;7.
- 22 62. de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S,
- 23 Bestebroer TM, et al. Screening of an FDA-approved compound library identifies four small-
- 24 molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.
- 25 Antimicrob Agents Chemother. 2014;58:4875–84.
- 26 63. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al.
- 27 Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome
- coronavirus infection. Antimicrob Agents Chemother. 2014;58:4885–93.
- 29 64. Shin JS, Jung E, Kim M, Baric RS, Go YY. Saracatinib Inhibits Middle East Respiratory
- 30 Syndrome-Coronavirus Replication In Vitro. Viruses. 2018;10.
- 31 65. Shen L, Niu J, Wang C, Huang B, Wang W, Zhu N, et al. High-Throughput Screening and
- 32 Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses. J Virol. 2019;93.
- 33 66. Corsello SM, Bittker JA, Liu Z, Gould J, McCarren P, Hirschman JE, et al. The Drug
- 34 Repurposing Hub: a next-generation drug library and information resource. Nat Med.
- **35** 2017;23:405–8.
- 36 67. Patel PC, Lee HSW, Ming AYK, Rath A, Deber CM, Yip CM, et al. Inside-out signaling
- 37 promotes dynamic changes in the carcinoembryonic antigen-related cellular adhesion molecule
- 38 1 (CEACAM1) oligomeric state to control its cell adhesion properties. J Biol Chem.
- 39 2013;288:29654–69.
- 40 68. Lambert DW, Clarke NE, Hooper NM, Turner AJ. Calmodulin interacts with angiotensin-
- 41 converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. FEBS Lett.
- 42 2008;582:385–90.
- 43 69. Lai ZW, Lew RA, Yarski MA, Mu F-T, Andrews RK, Smith AI. The identification of a
- 44 calmodulin-binding domain within the cytoplasmic tail of angiotensin-converting enzyme-2.
- 45 Endocrinology. 2009;150:2376–81.
- 46 70. Kitab B, Satoh M, Ohmori Y, Munakata T, Sudoh M, Kohara M, et al. Ribonucleotide
- 47 reductase M2 promotes RNA replication of hepatitis C virus by protecting NS5B protein from
- 48 hPLIC1-dependent proteasomal degradation. J Biol Chem. 2019;294:5759–73.
- 49 71. Shin HJ, Kim C, Cho S. Gemcitabine and Nucleos(t)ide Synthesis Inhibitors Are Broad-
- 50 Spectrum Antiviral Drugs that Activate Innate Immunity. Viruses. 2018;10.

- 72. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.
- 73. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, et al. Circos: an information aesthetic for comparative genomics. Genome Res. 2009;19:1639–45.

7

Figure Legends

Figure 1 Quantitative analysis of collected virus host-interactions. (A) Keynumbers describing the database that has been assembled. (B) Numbers of distinct interactions that have been collected for each virus. **(C)** Orthologous interaction conserved between several viruses. The thickness of the lines is proportional to the number of viruses for which the interaction was reported. Displayed graph was generated using Cytoscape [72]. **(D)** Circular diagram showing the proportion of shared host protein targets between analyzed coronaviruses. Display was obtained using the Circos table viewer [73]. (E) Innate immunity factors interacting with several coronavirus proteins.

Figure 2 KEGG pathways enriched in the list of coronavirus-interacting proteins. (A) Protein processing in endoplasmic reticulum (KEGG map ID: 04141). (B) Endocytosis (KEGG map ID: 04144). (C) RNA transport (KEGG map ID: 03013). (D) RIG-I-like receptor signaling (KEGG map ID: 04622). Host proteins interacting with coronavirus proteins are highlighted in red.

**Figure 3** Interactions of coronavirus proteins with metabolic pathways. Coronavirus-interacting proteins that are involved in cellular metabolism are displayed (i.e. with the KEGG tag "metabolic pathway"). Host factors were clustered and colored according to the specific pathways they belong to using KEGG annotation.

Figure 4 Interactions of coronavirus proteins with clusters of tightly connected proteins in the human interactome. We established a core list of host proteins for which multiple experimental evidences exist to support an interaction with coronavirus proteins. This includes virus-host interactions validated by different technics in one report or confirmed across multiple publications. Host proteins captured independently by different viral proteins were also included. Metascape was used to identify the six clusters that are presented (blue lines indicate PPIs from the human interactome). Supporting virus-host interactions are detailed in the left table. DAVID functional annotation tool was used to determine most statistically enriched GO terms and annotate the clusters (corrected p-values are indicated).

**Figure 5 Intersection between the coronavirus-host interactome and cellular targets of drugs inhibiting coronavirus replication.** Viral proteins are in red, host proteins in blue and small

- 1 molecules in green. Virus-host PPIs are from the coronavirus-host interactome. Compound-
- 2 target interactions were retrieved from the Drug Repurposing Hub database. For each
- 3 molecule, stars indicate how many screenings out of the four compiled for this analysis
- 4 identified their anti-coronavirus activity.

#### 1 Table 1

#### a- Kegg pathways enrichment in SARS-CoV-2 host protein targets (n=333)


Kegg pathway (Term)	Count	%	p-Value	Fold Enrichment	Benjamini p-value
Protein processing in endoplasmic reticulum	13	4	8,80E-05	4	1,70E-02
RNA transport	12	3,7	4,40E-04	3,6	4,10E-02


4 b- Kegg pathways enrichment in highly pathogenic hCoVs host protein targets (n=483)


Kegg pathway (Term)	Count	%	p-Value	Fold Enrichment	Benjamini p-value
RIG-I-like receptor signaling pathway	14	3	1,30E-07	6,6	3,00E-05
NF-kappa B signaling pathway	13	2,8	1,10E-05	4,9	8,00E-04
RNA transport	19	4,1	4,10E-06	3,6	4,50E-04
Protein processing in endoplasmic reticulum	18	3,9	1,30E-05	3,5	7,20E-04
Epstein-Barr virus infection	13	2,8	3,10E-04	3,5	1,10E-02
Influenza A	18	3,9	1,90E-05	3,4	8,40E-04
<u>Measles</u>	13	2,8	6,80E-04	3,2	2,10E-02


c- Kegg pathways enrichment in Coronaviruses host protein targets (n=1139)


- kegg pathways enficiment in colonaviruses host protein targets (ii-1135)					
Kegg pathway (Term)	Count	%	p-Value	Fold Enrichment	Benjamini p-value
Ribosome	60	5,5	1,10E-31	5,9	2,70E-29
RIG-I-like receptor signaling pathway	16	1,5	1,60E-04	3,1	5,60E-03
Protein processing in endoplasmic reticulum	37	3,4	5,20E-09	2,9	6,60E-07
RNA transport	33	3	1,00E-06	2,6	6,30E-05
Endocytosis	43	3,9	1,30E-07	2,4	1,10E-05
<u>Spliceosome</u>	24	2,2	1,10E-04	2,4	4,70E-03
<u>Phagosome</u>	26	2,4	1,00E-04	2,3	5,30E-03















HOST PROTEIN	VIRAL PROTEIN
АСТВ	IBV:M
CHEK2	SARS-CoV:NSP13
DDX5	IBV:N SARS-CoV:NSP13
DHX9	IBV:N TGEV:N
EIF4A2	TGEV:M
EIF4E2	SARS-CoV-2:NSP2 SARS-CoV:NSP2
FUS	IBV:N MHV:NSP2
HNRNPA2B1	IBV:N
HNRNPD	IBV:N MHV:NSP2
HNRNPF	IBV:N MHV:NSP2
KPNB1	MHV:NSP2 SARS-CoV:ORF6
PPIA	SARS-CoV:N SARS-CoV:NSP15
PPIH	SARS-CoV:NSP1
RPL13A	IBV:N MHV:NSP2
RPL19	IBV:N
RPL26	HCoV-OC43:N IBV:N TGEV:N
RPS13	IBV:N TGEV:N
RPS17	IBV:N SARS-CoV:ORF9B
RPS19	HCoV-OC43:N IBV:N
RPS20	SARS-CoV:ORF9B
RPS9	IBV:N TGEV:N
SRP54	MHV:NSP2 SARS-CoV-2:NSP8
TUBB	MHV:N
UPF1	IBV:N SARS-CoV-2:N
YWHAE	SARS-CoV:NSP7 SARS-CoV:ORF3A
DDX1	IBV:N IBV:NSP14 MHV:NSP2 SARS-CoV:NSP14 TGEV:N TGEV:NSP14
DDX21	IBV:N SARS-CoV-2:N
DDX58	PDCov:N PDCoV:ORF6 SARS-CoV:M
DDX38	MHV:NSP2 SARS-CoV:ORF9B
HNRNPA1	HCoV-OC43:N IBV:N MHV:N PEDV:N SARS-CoV:N
IFIH1	MERS-CoV:ORF4B PDCov:N PDCoV:ORF6
IGF2BP1	IBV:N MHV:NSP2
IKBKE	MERS-CoV:ORF4B PEDV:N SARS-CoV:M SARS-CoV:NSP3
MAVS	SARS-CoV:ORF9B
MEPCE	MHV:NSP2 SARS-CoV-2:NSP8
MOV10	IBV:N SARS-CoV-2:N
SSB	IBV:N MHV:NSP2
TBK1	MERS-CoV:ORF4B MHV:NSP3 PEDV:N SARS-CoV-2:NSP13 SARS-
	CoV:M SARS-CoV:NSP3
UBE2I	SARS-CoV:N
XRCC5	HCoV-OC43:N IBV:N
XRCC6	HCoV-OC43:N IBV:N
G3BP1	IBV:N MHV:NSP2 SARS-CoV-2:N
GSK3B	IBV:N SARS-CoV:N
HNRNPU	HCoV-OC43:N IBV:N TGEV:N
IKBKB	PEDV:ORF3 SARS-CoV:M
IKBKG	PEDV:NSP5
IRF3	MHV:NSP3 SARS-CoV:NSP3 SARS-CoV:ORF8AB SARS-CoV:ORF8B
ISG15	MERS-CoV:NSP3 MHV:NSP3 SARS-CoV:NSP3
NCL	HCoV-OC43:N IBV:N
MENT	IBV:N
NPM1	IBV:N HCOV-NI 63:NSP3 SARS-COV-NSP3
STING1	HCoV-NL63:NSP3 SARS-CoV:NSP3
	HCoV-NL63:NSP3 SARS-CoV:NSP3 HCoV-HKU1:M PDCov:N SARS-CoV:M SARS-CoV:NSP3 SARS-
STING1 TRAF3	HCoV-NL63:NSP3 SARS-CoV:NSP3 HCoV-HKU1:M PDCov:N SARS-CoV:M SARS-CoV:NSP3 SARS-CoV:ORF3A
STING1 TRAF3 YBX1	HCoV-NL63:NSP3 SARS-CoV:NSP3  HCoV-HKU1:M PDCov:N SARS-CoV:M SARS-CoV:NSP3 SARS-CoV:ORF3A  HCoV-OC43:N IBV:N
STING1 TRAF3 YBX1 BTF3	HCoV-NL63:NSP3 SARS-CoV:NSP3 HCoV-HKU1:M PDCov:N SARS-CoV:M SARS-CoV:NSP3 SARS-CoV:ORF3A HCoV-OC43:N IBV:N MHV:NSP2 SARS-CoV:NSP10
STING1 TRAF3 YBX1 BTF3 EEF1A1	HCoV-NL63:NSP3 SARS-CoV:NSP3 HCoV-HKU1:M PDCov:N SARS-CoV:M SARS-CoV:NSP3 SARS-CoV:ORF3A HCoV-OC43:N IBV:N MHV:NSP2 SARS-CoV:NSP10 SARS-CoV:N TGEV:N
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1	HCoV-NL63:NSP3 SARS-CoV:NSP3 HCoV-HKU1:M PDCov:N SARS-CoV:M SARS-CoV:NSP3 SARS-CoV:ORF3A HCoV-OC43:N IBV:N MHV:NSP2 SARS-CoV:NSP10 SARS-CoV:N TGEV:N HCoV-OC43:N IBV:N SARS-CoV-2:N
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1 PABPC4	HCoV-NL63:NSP3 SARS-CoV:NSP3 HCoV-HKU1:M PDCov:N SARS-CoV:M SARS-CoV:NSP3 SARS-CoV:ORF3A HCoV-OC43:N IBV:N MHV:NSP2 SARS-CoV:NSP10 SARS-CoV:N TGEV:N HCoV-OC43:N IBV:N SARS-CoV-2:N IBV:N SARS-CoV-2:N
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1 PABPC4 PPP1CA	HCoV-NL63:NSP3 SARS-CoV:NSP3 HCoV-HKU1:M PDCov:N SARS-CoV:M SARS-CoV:NSP3 SARS-CoV:ORF3A HCoV-OC43:N IBV:N MHV:NSP2 SARS-CoV:NSP10 SARS-CoV:N TGEV:N HCoV-OC43:N IBV:N SARS-CoV-2:N IBV:N SARS-CoV-2:N TGEV:ORF7
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1 PABPC4	HCoV-NL63:NSP3 SARS-CoV:NSP3 HCoV-HKU1:M PDCov:N SARS-CoV:M SARS-CoV:NSP3 SARS-CoV:ORF3A HCoV-OC43:N IBV:N MHV:NSP2 SARS-CoV:NSP10 SARS-CoV:N TGEV:N HCoV-OC43:N IBV:N SARS-CoV-2:N IBV:N SARS-CoV-2:N
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1 PABPC4 PPP1CA	HCoV-NL63:NSP3 SARS-CoV:NSP3 HCoV-HKU1:M PDCov:N SARS-CoV:M SARS-CoV:NSP3 SARS-CoV:ORF3A HCoV-OC43:N IBV:N MHV:NSP2 SARS-CoV:NSP10 SARS-CoV:N TGEV:N HCoV-OC43:N IBV:N SARS-CoV-2:N IBV:N SARS-CoV-2:N TGEV:ORF7
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1 PABPC4 PPP1CA PRKAR2B	HCoV-NL63:NSP3 SARS-CoV:NSP3 HCoV-HKU1:M PDCov:N SARS-CoV:M SARS-CoV:NSP3 SARS-CoV:ORF3A HCoV-OC43:N IBV:N MHV:NSP2 SARS-CoV:NSP10 SARS-CoV:N TGEV:N HCoV-OC43:N IBV:N SARS-CoV-2:N IBV:N SARS-CoV-2:N TGEV:ORF7 MHV:NSP2 SARS-CoV-2:NSP13
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1 PABPC4 PPP1CA PRKAR2B RAB5C	HCoV-NL63:NSP3 SARS-CoV:NSP3 HCoV-HKU1:M PDCov:N SARS-CoV:M SARS-CoV:NSP3 SARS-CoV:ORF3A HCoV-OC43:N IBV:N MHV:NSP2 SARS-CoV:NSP10 SARS-CoV:N TGEV:N HCoV-OC43:N IBV:N SARS-CoV-2:N IBV:N SARS-CoV-2:N TGEV:ORF7 MHV:NSP2 SARS-CoV-2:NSP13 MHV:NSP2 SARS-CoV-2:NSP7
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1 PABPC4 PPP1CA PRKAR2B RAB5C USP10 CKAP5	HCoV-NL63:NSP3 SARS-CoV:NSP3 HCoV-HKU1:M PDCov:N SARS-CoV:M SARS-CoV:NSP3 SARS-CoV:ORF3A HCoV-OC43:N IBV:N MHV:NSP2 SARS-CoV:NSP10 SARS-CoV:N TGEV:N HCoV-OC43:N IBV:N SARS-CoV-2:N IBV:N SARS-CoV-2:N TGEV:ORF7 MHV:NSP2 SARS-CoV-2:NSP13 MHV:NSP2 SARS-CoV-2:NSP7 IBV:N MHV:NSP2
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1 PABPC4 PPP1CA PRKAR2B RAB5C USP10	HCOV-NL63:NSP3 SARS-COV:NSP3  HCOV-HKU1:M PDCov:N SARS-CoV:M SARS-CoV:NSP3 SARS-CoV:ORF3A  HCOV-OC43:N IBV:N  MHV:NSP2 SARS-CoV:NSP10  SARS-CoV:N TGEV:N  HCOV-OC43:N IBV:N SARS-CoV-2:N  IBV:N SARS-COV-2:N  TGEV:ORF7  MHV:NSP2 SARS-COV-2:NSP13  MHV:NSP2 SARS-CoV-2:NSP7  IBV:N MHV:NSP2  MHV:NSP2 SARS-COV-NSP1
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1 PABPC4 PPP1CA PRKAR2B RAB5C USP10 CKAP5	HCOV-NL63:NSP3 SARS-COV:NSP3  HCOV-HKU1:M PDCOv:N SARS-COV:M SARS-COV:NSP3 SARS-COV:ORF3A  HCOV-OC43:N IBV:N  MHV:NSP2 SARS-COV:NSP10  SARS-COV:N TGEV:N  HCOV-OC43:N IBV:N SARS-COV-2:N  IBV:N SARS-COV-2:N  TGEV:ORF7  MHV:NSP2 SARS-COV-2:NSP13  MHV:NSP2 SARS-COV-2:NSP7  IBV:N MHV:NSP2  MHV:NSP2 SARS-COV-SP7  SARS-COV:NSP14 SARS-COV:ORF3A SARS-
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1 PABPC4 PPP1CA PRKAR2B RAB5C USP10 CKAP5 DCTN2	HCOV-NL63:NSP3 SARS-COV:NSP3  HCOV-HKU1:M PDCOv:N SARS-COV:M SARS-COV:NSP3 SARS-COV:ORF3A  HCOV-OC43:N IBV:N  MHV:NSP2 SARS-COV:NSP10  SARS-COV:N TGEV:N  HCOV-OC43:N IBV:N SARS-COV-2:N  IBV:N SARS-COV-2:N  TGEV:ORF7  MHV:NSP2 SARS-COV-2:NSP13  MHV:NSP2 SARS-COV-2:NSP7  IBV:N MHV:NSP2  MHV:NSP2 SARS-COV-SHSP1  SARS-COV:ORF3A SARS-COV:ORF3A SARS-COV:ORF3B SARS-COV:ORF6
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1 PABPC4 PPP1CA PRKAR2B RAB5C USP10 CKAP5 DCTN2 FBF1 MARK1	HCOV-NL63:NSP3 SARS-COV:NSP3  HCOV-HKU1:M PDCOV:N SARS-COV:M SARS-COV:NSP3 SARS-COV:ORF3A  HCOV-OC43:N IBV:N  MHV:NSP2 SARS-COV:NSP10  SARS-COV:N TGEV:N  HCOV-OC43:N IBV:N SARS-COV-2:N  IBV:N SARS-COV-2:N  TGEV:ORF7  MHV:NSP2 SARS-COV-2:NSP13  MHV:NSP2 SARS-COV-2:NSP7  IBV:N MHV:NSP2  MHV:NSP2 SARS-COV-0:NSP1  SARS-COV:ORF3A SARS-COV:ORF3A SARS-COV:ORF3B SARS-COV:ORF6  MHV:NSP14 MHV:NSP16  MHV:NSP2 SARS-COV-2:ORF9B
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1 PABPC4 PPP1CA PRKAR2B RAB5C USP10 CKAP5 DCTN2 FBF1 MARK1 MARK2	HCOV-NL63:NSP3 SARS-COV:NSP3  HCOV-HKU1:M PDCOV:N SARS-COV:M SARS-COV:NSP3 SARS-COV:ORF3A  HCOV-OC43:N IBV:N  MHV:NSP2 SARS-COV:NSP10  SARS-COV:N TGEV:N  HCOV-OC43:N IBV:N SARS-COV-2:N  IBV:N SARS-COV-2:N  TGEV:ORF7  MHV:NSP2 SARS-COV-2:NSP13  MHV:NSP2 SARS-COV-2:NSP7  IBV:N MHV:NSP2  MHY:NSP2 SARS-COV-2:NSP1  SARS-COV:ORF3A SARS-COV:ORF3B SARS-COV:ORF3B SARS-COV:ORF6B  MHV:NSP2 SARS-COV-2:ORF9B  MHV:NSP2 SARS-COV-2:ORF9B  MHV:NSP2 SARS-COV-2:ORF9B
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1 PABPC4 PPP1CA PRKAR2B RAB5C USP10 CKAP5 DCTN2 FBF1 MARK1 MARK2 MARK3	HCOV-NL63:NSP3 SARS-COV:NSP3  HCOV-HKU1:M PDCOV:N SARS-COV:M SARS-COV:NSP3 SARS-COV:ORF3A  HCOV-OC43:N IBV:N  MHV:NSP2 SARS-COV:NSP10  SARS-COV:N TGEV:N  HCOV-OC43:N IBV:N SARS-COV-2:N  IBV:N SARS-COV-2:N  TGEV:ORF7  MHV:NSP2 SARS-COV-2:NSP13  MHV:NSP2 SARS-COV-2:NSP7  IBV:N MHV:NSP2  MHV:NSP2 SARS-COV-0:NSP1  SARS-COV:NSP14 SARS-COV:ORF14 SARS-COV:ORF3A SARS-COV:ORF3B SARS-COV:ORF6  MHV:NSP2 SARS-COV-2:ORF9B SARS-COV:NSP13  MHV:NSP2 SARS-COV-2:ORF9B SARS-COV:NSP13  MHV:NSP2 SARS-COV-2:ORF9B SARS-COV:NSP13
STING1 TRAF3 YBX1 BTF3 EEF1A1 PABPC1 PABPC4 PPP1CA PRKAR2B RAB5C USP10 CKAP5 DCTN2 FBF1 MARK1 MARK2	HCOV-NL63:NSP3 SARS-COV:NSP3  HCOV-HKU1:M PDCOV:N SARS-COV:M SARS-COV:NSP3 SARS-COV:ORF3A  HCOV-OC43:N IBV:N  MHV:NSP2 SARS-COV:NSP10  SARS-COV:N TGEV:N  HCOV-OC43:N IBV:N SARS-COV-2:N  IBV:N SARS-COV-2:N  TGEV:ORF7  MHV:NSP2 SARS-COV-2:NSP13  MHV:NSP2 SARS-COV-2:NSP7  IBV:N MHV:NSP2  MHY:NSP2 SARS-COV-2:NSP1  SARS-COV:ORF3A SARS-COV:ORF3B SARS-COV:ORF3B SARS-COV:ORF6B  MHV:NSP2 SARS-COV-2:ORF9B  MHV:NSP2 SARS-COV-2:ORF9B  MHV:NSP2 SARS-COV-2:ORF9B

#### mRNA catabolic process (p=10<sup>-17</sup>)



## Regulation of type I interferon production ( $p=10^{-12}$ )

